OA13233A - Novel composition comprising rosiglitazone and another antidiabetic agent. - Google Patents

Novel composition comprising rosiglitazone and another antidiabetic agent. Download PDF

Info

Publication number
OA13233A
OA13233A OA1200600045A OA1200600045A OA13233A OA 13233 A OA13233 A OA 13233A OA 1200600045 A OA1200600045 A OA 1200600045A OA 1200600045 A OA1200600045 A OA 1200600045A OA 13233 A OA13233 A OA 13233A
Authority
OA
OAPI
Prior art keywords
core
coating
dosage form
erodable
oral dosage
Prior art date
Application number
OA1200600045A
Other languages
English (en)
Inventor
Peter John Coles
Donald Colin Maskenzie
Paul Norman Mudd Jr
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27840010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13233(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of OA13233A publication Critical patent/OA13233A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200600045A 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent. OA13233A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0318824.0A GB0318824D0 (en) 2003-08-11 2003-08-11 Novel composition

Publications (1)

Publication Number Publication Date
OA13233A true OA13233A (en) 2006-12-13

Family

ID=27840010

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200600045A OA13233A (en) 2003-08-11 2004-08-09 Novel composition comprising rosiglitazone and another antidiabetic agent.

Country Status (37)

Country Link
US (1) US20080206336A1 (is)
EP (1) EP1663191B1 (is)
JP (1) JP4714147B2 (is)
KR (1) KR20060071396A (is)
CN (2) CN1835741B (is)
AP (1) AP2006003489A0 (is)
AR (1) AR045230A1 (is)
AT (1) ATE455542T1 (is)
AU (1) AU2004262933B2 (is)
BR (1) BRPI0413419A (is)
CA (1) CA2534480A1 (is)
CY (1) CY1109923T1 (is)
DE (1) DE602004025257D1 (is)
DK (1) DK1663191T3 (is)
EA (2) EA011550B1 (is)
EC (1) ECSP066338A (is)
ES (1) ES2339554T3 (is)
GB (1) GB0318824D0 (is)
HK (1) HK1092051A1 (is)
HR (1) HRP20100160T1 (is)
IL (1) IL173177A0 (is)
IS (1) IS2745B (is)
MA (1) MA27996A1 (is)
MX (1) MXPA06001629A (is)
MY (1) MY151053A (is)
NO (1) NO20061161L (is)
NZ (1) NZ544632A (is)
OA (1) OA13233A (is)
PE (1) PE20050357A1 (is)
PL (1) PL1663191T3 (is)
PT (1) PT1663191E (is)
SG (1) SG165178A1 (is)
SI (1) SI1663191T1 (is)
TW (1) TW200517146A (is)
UA (1) UA82537C2 (is)
UY (1) UY28461A1 (is)
WO (1) WO2005013956A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
EP2318001A4 (en) * 2008-07-18 2013-02-20 Valeant Pharmaceuticals Int FORMULATION WITH MODIFIED RELEASE AND USE METHOD
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2011161521A1 (en) * 2010-06-21 2011-12-29 Lupin Limited Compositions comprising metformin and rosiglitazone
PL2590634T3 (pl) * 2010-07-09 2016-10-31 Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny
CN102727459A (zh) * 2011-04-15 2012-10-17 江苏豪森医药集团有限公司 一种具有第一和第二活性药物的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
ES2221370T3 (es) * 1998-04-03 2004-12-16 Egalet A/S Composicion de liberacion controlada.
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
EP1001014B1 (en) * 1998-11-10 2006-01-11 The Procter & Gamble Company Bleaching compositions
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
EA007610B1 (ru) * 1998-11-12 2006-12-29 Смитклайн Бичам Плс Таблетка с энтеропокрытием, обеспечивающая отсроченное высвобождение
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
ES2290130T3 (es) * 2000-05-01 2008-02-16 Aeropharm Technology, Llc Formulacion de nucleo.
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
GB0120835D0 (en) * 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Also Published As

Publication number Publication date
TW200517146A (en) 2005-06-01
IS2745B (is) 2011-08-15
NZ544632A (en) 2009-03-31
EA200600400A1 (ru) 2006-08-25
EA200800966A1 (ru) 2009-04-28
AU2004262933A1 (en) 2005-02-17
AP2006003489A0 (en) 2006-02-28
ATE455542T1 (de) 2010-02-15
UA82537C2 (uk) 2008-04-25
UY28461A1 (es) 2005-03-31
PE20050357A1 (es) 2005-06-01
MXPA06001629A (es) 2006-04-28
ES2339554T3 (es) 2010-05-21
CN1835741A (zh) 2006-09-20
IS8337A (is) 2006-03-02
MY151053A (en) 2014-03-31
CA2534480A1 (en) 2005-02-17
BRPI0413419A (pt) 2006-10-10
CN1835741B (zh) 2011-12-14
HK1092051A1 (en) 2007-02-02
KR20060071396A (ko) 2006-06-26
JP2007501830A (ja) 2007-02-01
US20080206336A1 (en) 2008-08-28
EP1663191A1 (en) 2006-06-07
SG165178A1 (en) 2010-10-28
AR045230A1 (es) 2005-10-19
NO20061161L (no) 2006-03-10
CY1109923T1 (el) 2014-09-10
CN102397551A (zh) 2012-04-04
EA011550B1 (ru) 2009-04-28
JP4714147B2 (ja) 2011-06-29
WO2005013956A1 (en) 2005-02-17
IL173177A0 (en) 2006-06-11
PL1663191T3 (pl) 2010-06-30
AU2004262933B2 (en) 2009-12-10
PT1663191E (pt) 2010-03-16
HRP20100160T1 (hr) 2010-05-31
ECSP066338A (es) 2006-07-28
DK1663191T3 (da) 2010-04-26
GB0318824D0 (en) 2003-09-10
SI1663191T1 (sl) 2010-05-31
MA27996A1 (fr) 2006-07-03
EP1663191B1 (en) 2010-01-20
DE602004025257D1 (de) 2010-03-11

Similar Documents

Publication Publication Date Title
US9144547B2 (en) Oral dosage form for controlled drug release
CA2617715A1 (en) Pharmaceutical composition comprising a dpp-iv inhibitor
OA13233A (en) Novel composition comprising rosiglitazone and another antidiabetic agent.
EA200701680A1 (ru) Лекарственная форма для перорального введения, содержащая розиглитазон
JP5279757B2 (ja) 薬物制御放出のための経口用剤形
WO2006053323B1 (en) Inhibitors of hiv-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
EA200101101A1 (ru) Новый фармацевтический препарат
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
WO2000063206A3 (en) Thiazolidinedione derivative and its use as antidiabetic
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
AP2003002737A0 (en) Tartrate salts of thiazolidinedione derivatives
WO2002028857A8 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
TH62393A (th) สารผสมชนิดใหม่